Standard Biotools (LAB) Net Cash Flow Growth (1y) (2011 - 2026)
Standard Biotools (LAB) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 187.02 Bn | 179.73 Bn | 6.27 Bn | -53.07% |
| 2 | Stryker | 132.07 Bn | 129.19 Bn | 3.81 Bn | 17.60% |
| 3 | Medtronic | 111.38 Bn | 102.16 Bn | 6.41 Bn | 10.50% |
| 4 | Boston Scientific | 68.98 Bn | 67.53 Bn | 3.61 Bn | -283.58% |
| 5 | Edwards Lifesciences | 48.32 Bn | 44.65 Bn | 1.29 Bn | -564.44% |
| 6 | Dexcom | 28.91 Bn | 27.80 Bn | 750.30 Mn | -31.84% |
| 7 | GE HealthCare Technologies | 28.83 Bn | 26.55 Bn | 1.98 Bn | -394.13% |
| 8 | Smith & Nephew | 28.10 Bn | 27.52 Bn | - | - |
| 9 | Koninklijke Philips | 24.30 Bn | 21.26 Bn | 2.01 Bn | 78.82% |
| 10 | Standard Biotools | 302.10 Mn | -153.08 Mn | 11.31 Mn | 1,019.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,019.85% |
| Dec 31, 2025 | 79.91% |
| Sep 30, 2025 | 50.65% |
| Jun 30, 2025 | 140.48% |
| Mar 31, 2025 | -106.66% |
| Dec 31, 2024 | -52.06% |
| Sep 30, 2024 | 6.00% |
| Jun 30, 2024 | -159.75% |
| Mar 31, 2024 | 634.53% |
| Dec 31, 2023 | -235.52% |
| Sep 30, 2023 | -350.30% |
| Jun 30, 2023 | -35.81% |
| Mar 31, 2023 | 1,885.84% |
| Sep 30, 2022 | 64.59% |
| Jun 30, 2022 | 218.27% |
| Mar 31, 2022 | 108.58% |
| Sep 30, 2021 | -235.03% |
| Jun 30, 2021 | -581.95% |
| Mar 31, 2021 | -248.87% |
| Dec 31, 2020 | 3.80% |